Literature DB >> 22177457

Tumor necrosis factor alpha-308 and Lymphotoxin alpha+252 genetic polymorphisms and the susceptibility to non-Hodgkin lymphoma in Egypt.

Azza Ibrahim1, Hala Abdel Rahman, Mervat Khorshied, Rania Sami, Nelly Nasr, Ola Khorshid.   

Abstract

Genetic polymorphism within the regulatory regions of tumor necrosis factor-alpha (TNF-α) and Lymphotoxin-alpha (LT-α) may be involved in the development of lymphoid malignancies. The aim of the current study was to investigate the effect of TNFα-308 and LTα+252 genetic polymorphism on susceptibility to non-Hodgkin lymphoma (NHL) in Egypt. Genotyping of the studied genes by restriction fragment length polymorphism polymerase chain reaction was conducted on 84 NHL and 100 healthy controls and revealed that TNFα-308 homotype (AA) was significantly higher in NHL patients and conferred sixfold increased risk of NHL (OR=5.9, 95%CI=2.3-16.1). Moreover, TNFα/LTα high-producer haplotypes were significantly higher in NHL patients and conferred increased risk of NHL (OR=4.59, 95%CI=2.19-9.42).
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177457     DOI: 10.1016/j.leukres.2011.11.016

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  The link between genetic polymorphism of glutathione-S-transferases, GSTM1, and GSTT1 and diffuse large B-cell lymphoma in Egypt.

Authors:  Hala A Abdel Rahman; Mervat M Khorshied; Haidy H Elazzamy; Ola M Khorshid
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-07       Impact factor: 4.553

2.  Genetic variation in the TLR and NF-κB pathways and cervical and vulvar cancer risk: a population-based case-control study.

Authors:  Clara Bodelon; Margaret M Madeleine; Lisa G Johnson; Qin Du; Denise A Galloway; Mari Malkki; Effie W Petersdorf; Stephen M Schwartz
Journal:  Int J Cancer       Date:  2013-08-05       Impact factor: 7.396

3.  Genetic Variations of Tumor Necrosis Factor -α-308 and Lymphtoxin-α+252 in Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia Patients.

Authors:  Hajar Nasiri; Safar Farajnia; Azim Rezamand; Ali Akbar Movassaghpour; Heydar Ali Esmaeili; Amir Monfaredan; Naser Mobarra; Nasser Rahimifar; Leyla Sahebi; Majid Farshdousti Hagh
Journal:  Iran J Basic Med Sci       Date:  2013-09       Impact factor: 2.699

4.  Different role of tumor necrosis factor-α polymorphism in non-Hodgkin lymphomas among Caucasian and Asian populations: a meta-analysis.

Authors:  Kan Zhai; Jie Ding; Yan Zhou
Journal:  Int J Mol Sci       Date:  2014-05-05       Impact factor: 5.923

5.  Tumor necrosis factor-308 polymorphism with the risk and prognosis of non-Hodgkin lymphomas: a meta-analysis study.

Authors:  Sicheng Gao; Guoqing Zhu; Yan Lin; Xingliang Fan; Pingan Qian; Junfeng Zhu; Yongchun Yu
Journal:  Onco Targets Ther       Date:  2016-03-21       Impact factor: 4.147

Review 6.  A Review of Cancer Genetics and Genomics Studies in Africa.

Authors:  Solomon O Rotimi; Oluwakemi A Rotimi; Bodour Salhia
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

7.  Association of TNF-α rs1800629 with Adult Acute B-Cell Lymphoblastic Leukemia.

Authors:  Ezeldine K Abdalhabib; Abdulrahman Algarni; Muhammad Saboor; Fehaid Alanazi; Ibrahim K Ibrahim; Ayman H Alfeel; Abdullah M Alanazi; Abdulmajeed M Alanazi; Abdulaziz M Alruwaili; Muath H Alanazi; Nahla A Alshaikh
Journal:  Genes (Basel)       Date:  2022-07-13       Impact factor: 4.141

8.  The association between the polymorphisms of TNF-α and non-Hodgkin lymphoma: a meta-analysis.

Authors:  Yong-Qiao He; Jin-Hong Zhu; Shao-Yi Huang; Zhuo Cui; Jing He; Wei-Hua Jia
Journal:  Tumour Biol       Date:  2014-09-10

9.  Association analysis of genetic variants in the ghrelin and tumor necrosis factor α genes and the risk for non-Hodgkin's lymphoma in Kuwaitis.

Authors:  Maryam H Alrashid; Ahmad Al-Serri; Salem H Alshemmari; Jeethu Anu Geo; Suzanne A Al-Bustan
Journal:  Cancer Biomark       Date:  2021       Impact factor: 4.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.